99m Tc-sulesomab studies were regarded as true-positives and 6 patients had true-negative scans. One patient had a false-positive scan (abnormal uptake with negative microbiology) and 3 had false-negative scans (infection confirmed but a negative scan). Conclusion: In suspected soft tissue infection, 99m Tc-sulesomab imaging has a sensitivity of 88% with a specificity of 86% and overall accuracy of 87%.
Introduction
Accurate, early diagnosis of infection or inflammation is critical for optimal clinical management. Imaging by conventional modalities, namely computed tomography (CT), ultrasound or magnetic resonance imaging, is often unrewarding in patients with pyrexia of unknown origin. In postsurgical patients, interpretation of images may be very difficult due to the presence of postoperative changes. Nuclear medicine provides a variety of radiopharmaceuticals, such as technetium-99m ( 99m Tc)-labelled methyldiphosphonate, gallium-67, radiolabelled monoclonal antibodies, 99m Tc-labelled nanocolloids and
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Although labelled white-cell imaging is normally seen as the 'gold standard', cell preparation is time consuming, technically demanding and also requires manipulation of blood products.
99m Tc-sulesomab (LeukoScan, Immunomedics, New Plains, N.J., USA) is a technetium-labelled murine monoclonal Fab antibody fragment, the epitope of which is directed to a granulocyte surface protein (NCA-90 surface antigen). It is currently licensed in Europe for patients with suspected bone or joint infections [1] . The mechanism of action is not clear, as recent work has failed to show binding of 99m Tc-sulesomab to circulating leucocytes [2] . However, studies with Tcsulesomab have shown that sensitivity, specificity and diagnostic accuracy are comparable to labelled white cells in the detection of osteomyelitis [3] . Most of the published use of 99m Tc-sulesomab has been within the context of suspected bone and joint infections, and it has been reported to be useful in a number of soft tissue infections such as endocarditis, appendicitis and infected vascular graft [4] .
The purpose of this study was to retrospectively assess the use of 99m Tc-sulesomab in the non-orthopaedic setting and to determine its overall accuracy in identifying soft tissue infections. Tc-sulesomab scan. The request forms of all these patients were reviewed, and those suspected of or subsequently found to have infection within bone were excluded from analysis. A total of 124 adult patients had undergone imaging with 99m Tc-sulesomab during the study period. Of these, 34 were performed for suspected soft tissue infection (20 male, 14 female; age 31-71 years). These patients' clinical notes, microbiology reports and other imaging findings were then reviewed to determine the clinical outcome of the patient.
Patients and Methods

Patients
Radiopharmaceutical and Scan Procedure 99m Tc-sulesomab (LeukoScan) was supplied as a commercial kit and reconstituted with up to 20 mCi (740 MBq) 99m Tc. It was injected intravenously within 4 h of reconstitution. Whole-body planar imaging was performed at 1 and 4 h after injection with a low-energy high-resolution collimator, table speed 8 cm/min, using a Prism 2000 XP (Phillips Picker, Eindhoven, the Netherlands). Planar images were reviewed by the nuclear medicine physician on duty at 1 and 4-6 h. Single-photon emission computed tomography (SPECT) was then performed if it was thought that the technique might be useful. Images were iteratively reconstructed using 6 iterations and ordered subset expectation maximization and filtered using a count-optimised low-pass Butterworth filter. They were then displayed in the standard 3 orthogonal planes -transverse, sagittal and coronal. Images were read by a physician of nuclear medicine. A study was recorded as positive if there was focal non-physiological accumulation of 99m Tc-sulesomab that increased with time compared to background uptake in both image sets. The study was also regarded as positive if the uptake of 99m Tc-sulesomab was markedly increased compared to expected physiological activity at that site in the first image and that level of activity was maintained in the second image set. If there was focal uptake which did not increase with time or even decreased, this was reported as negative. The results were interpreted as true-positive if the uptake correlated anatomically with the site from which infected fluid was obtained and/or with the site of abnormality reported on other imaging or if there was clinical correlation with the referring clinician's evaluation of the patient.
A true-negative result was determined as being no abnormal accumulation of 99m Tc-sulesomab and subsequent negative microbiological and/or histological assessment, which, together with a minimum 6-month clinical follow-up, failed to show any evidence of infection. No patients died, though one was lost to follow-up during this 6-month period.
Results
Of 34 studies, 21 were true-positive ( table 1 ) . These included 13 patients for whom a pathological agent was isolated and identified. Of these, 7 patients had Gram-positive infections with different Staphylococcus species. Gram-negative organisms were responsible for 5 of the infections correctly identified by the 99m Tc-sulesomab and the remaining patient had a fungal infection. In the other 8 patients, the diagnosis was confirmed by radiology, other blood tests and surgical correlation. There was a single false-positive study, with uptake in a malignant but non-infected pericarditis. Tc-sulesomab showed positive uptake in 11 patients with intra-abdominal infection ( fig. 1 , 2 ) . This was identified correctly despite the fact that there is some Tcsulesomab accumulation in the normal bowel and renal tract. There were 5 intrathoracic sites of infection includ-ing mediastinitis ( fig. 3 ) and bacterial endocarditis. An infected buttock abscess was also identified ( fig. 4 ) . In both the thorax and the abdomen, the use of SPECT, especially in the later 4-to 6-hour image, helped determine that the activity was not physiological and therefore identify the site of infection. Tc-sulesomab was also able to identify a case of malignant otitis externa, an infected vascular graft ( fig. 5 ), a dental abscess and oral candidiasis.
There were 6 true-negative studies, in which a negative study was followed up by negative cultures with no clinical features to suggest ongoing infection during at least 6 months of follow-up after the scan. There were 3 falsenegative studies. One patient had an Enterococcus septicaemia, the origin of which was presumed to be the gall bladder, but no abnormal uptake of 99m Tc-sulesomab was seen at this site. Another patient had a pneumococcal endocarditis, but the 99m Tc-sulesomab chest SPECT demonstrated only normal physiological uptake. The third patient had a subhepatic abscess which was not identified by 99m Tc-sulesomab but was subsequently correctly lo- calised using 67 Ga-citrate imaging. These results gave an overall sensitivity of 88%. Although the numbers are small, specificity was 86%. A positive predictive value of 95% and a negative predictive value of 66% were calculated. The overall accuracy of 99m Tc-sulesomab in soft tissue infection was calculated as 87%.
Three patients were unevaluable. In 1 patient, there was uptake in the soft tissue surrounding the site of central line insertion, and although confirmation of an Enterococcus infection was noted on the nuclear medicine request form, the patient's records were missing; therefore, it was not possible to confirm this finding. Another patient was not available for follow-up, and the third patient had a presumed diagnosis of inflammatory bowel disease with caecal uptake of 99m Tc-sulesomab, but this could not be confirmed.
Discussion
This study demonstrates the clinical utility of 99m Tcsulesomab as an imaging agent for suspected soft tissue infection. Compared to previous studies for orthopaedic infection, the sensitivity and specificity of 99m Tc-sulesomab for soft tissue infection is slightly less than when it is used for identifying bone and joint infections. For bone and joint infection, the sensitivity is 93% and specificity 89% [4] compared to a sensitivity of 88% and a specificity of 86% for soft tissue infections. However, the small sample size in this study means that an accurate comparison is difficult and this difference may not be significant. In addition, this is a retrospective study, and some caution must be exercised when comparing these results to those of a prospective trial, as there is a bias towards choosing patients with the disease in a retrospective study and it may be that in a full prospective trial, the accuracy of the 99m Tc-sulesomab may be less than in our series of patients.
The patients selected in our study were imaged with 99m Tc-sulesomab either by serendipity (for example, the suspected infection was in fact within the soft tissues and not bone) or pragmatism (the 'Friday' patient presenting when no pharmacist is available for cell labelling and a prompt result is needed). This will lead to some distortion of the population studied, but the wide range of sites and types of infection identified in our study suggest that there is a fairly eclectic group of clinical situations in which 99m Tc-sulesomab may be useful. A meta-analysis of different imaging techniques for intra-abdominal infections published a sensitivity of 88% and a specificity of 93% in 682 patients imaged with 111 Inlabelled white cells, while for 99m Tc-HMPAO-labelled leucocytes, the combined sensitivity was 88% and the specificity was 91% in 1,427 patients [5] . Our figures, though not referring exclusively to abdominal infection, show a similar sensitivity and specificity. Clearly, this would need to be tested in the setting of a formal randomised control trial. There are limitations when comparing a single-site review of 34 patients with such a large meta-analysis, but it does suggest that this agent should be considered for further evaluation as an agent for imaging suspected soft tissue infection, as long as the caveat on positivity (e.g. increasing accumulation over time at a non-physiological site) is maintained.
There are certain clinical advantages in using 99m
Tcsulesomab, as no cell labelling is required and preparation of the product takes only about 30 min. It could be particularly attractive when considering imaging patients in whom cell labelling is not desirable or for those in whom the retrovirus or hepatitis infection status is unknown or positive. It could also be useful in cases where speed of diagnosis is important. This is illustrated in our series for each patient ( table 1, fig. 3 ), where a life-threatening mediastinal infection was identified in a comatose patient who was known be an intravenous drug user, but for whom full counselling for an HIV test (a legal requirement in the UK) was clearly not possible.
When comparing the results from other antibodybased products, such as BW150/183 [6, 7] , the main characteristic of 99m Tc-sulesomab is the high persistent blood pool activity, low or minimal bone marrow activity but possibly more liver, bowel and urinary activity. This is probably due to the fact that as a Fab fragment, there is little immunogenic reaction and as a consequence of this, not much activity is cleared from the blood into the bone marrow and spleen.
99m Tc-sulesomab has a low rate ( ! 5%) of producing human anti-mouse antibodies [8] , and thus repeat imaging, if necessary, could be done safely in the majority of patients.
A full understanding of the mechanism of action of 99m Tc-sulesomab should be sought because without this it is impossible to predict those clinical situations where 99m Tc-sulesomab may be used and those where it will be inaccurate.
Conclusion
99m Tc-sulesomab is able to identify a wide range of soft tissue infections in a variety of clinical situations with a range of causative organisms. The results of this retrospective study indicate sufficient accuracy to justify a full prospective study on the use of 99m Tc-sulesomab in presumed soft tissue infection.
